The examination of the effects of Teneligliptin on blood glucose and albuminuria in type 2 diabetic patients with nephropathy, whose glycemic control is insufficient.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 14 Jun 2017 Planned End Date changed from 31 Dec 2016 to 20 Sep 2017.
- 27 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2014 New trial record